CD19 and B-cell chronic lymphocytic leukemia: Meta-analysis of 42 trials of anti-CD19 CAR T-cells in various B cell hematologic malignancies showed higher complete response (CR) rates of 77% in acute lymphoblastic leukemia patients (ALL) versus 25% in chronic lymphocytic leukemia (CLL) and 54% in non-Hodgkin lymphoma (NHL) (2).